-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
-
Summary
-
BriaCell Therapeutics Corp. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q2 2021 to Q2 2023.
- BriaCell Therapeutics Corp. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending July 31, 2023 was $4.91M, a 22.4% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)